ICU sedation, delirium & recovery
Propranolol As an Anxiolytic to Reduce the Use of Sedatives for Critically Ill Adults Receiving Mechanical Ventilation (PROACTIVE): An Open-Label Randomized Controlled Trial
Authors' conclusion
Propranolol is an inexpensive drug that effectively lowered the need for sedatives in critically ill patients managed in the COVID-19 pandemic.
Study context
- Population
- Nonparalyzed mechanically ventilated patients requiring high-dose sedatives
- Participants
- 72 participants
- Comparison
- Intervention vs Controls
- Primary endpoint
- Mean change in 24 hours dose of sedative from baseline
- Follow-up
- Day 3
Methodological detailsopen-label, multicentre (three academic hospitals), Enrolled January 2021 to October 2022, Propranolol received for a mean of 10 days (mean daily dose, 90 mg)
- Open-label
- Multicentre (three academic hospitals)
- Enrolled January 2021 to October 2022
- Propranolol received for a mean of 10 days (mean daily dose, 90 mg)
Primary result
As reported in the abstract
Decrease in sedative dose from baseline
P = 0.048
Further findings
Sedation assessments within target range
P < 0.0001
Mortality and adverse events
- No differences in mortality or adverse events
Original publication
Propranolol As an Anxiolytic to Reduce the Use of Sedatives for Critically Ill Adults Receiving Mechanical Ventilation (PROACTIVE): An Open-Label Randomized Controlled Trial. Crit Care Med. Published 21 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →